GLP-1 Receptor Agonists and the Risk of Thyroid Cancer.

Overview of attention for article published in Diabetes Care, November 2022

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (97th percentile)

Mentioned by

news: 67 news outlets
blogs: 5 blogs
twitter: 262 X users
patent: 1 patent
facebook: 3 Facebook pages

wikipedia: 7 Wikipedia pages
reddit: 60 Redditors
video: 3 YouTube creators
bluesky: 4 Bluesky users
podcasts: 2 podcasts

Readers on

mendeley: 208 Mendeley

So far, Altmetric has seen 4 Bluesky posts from 4 Bluesky users, with an upper bound of 955 followers.

Les GLP-1, à force de tout traiter, vont aussi produire tous les effets indésirables du monde... diabetesjournals.org/care/article...

Il fallait s'y attendre, découverte de risque augmenté de nouveaux EI graves, chez les pers prenant un agoniste GLP-1 pdt plusieurs années. Gageons que ce n'est que le début, et que la prescription à de très larges cohortes de patients mettra à jour d'aut…

Stupid Effing Trumpers....THEY RUIN EVERYTHING https://bsky.app/profile/did:plc:u4togqutxn3bfw7odv3aaqbs/post/3lccc6jm6ac24

Ozempic is a GLP-1 like Receptor Agonists and scientist have found a link between drugs with GLP-1 and Thyroid Cancer after a 1-3 year treatment. Biden is proposing Medicare to cover Ozempic for millions of Americans who are not diabetic, but simply ove…

This page shows the most recent Bluesky posts that mention this research output. Click here to find out how to access more activity.